

Rubicon

FY13 results

Strong progress from both Tenon and ArborGen

FY13 saw Tenon and ArborGen improve their financial performance and put in place banking facilities for their next growth phases. These results reinforce our view that Rubicon's (RBC) share price understates the underlying value of its investments – worth c NZ\$0.90 per share – and we expect to see this discount narrow over time.

Year end	Revenue (US\$m)	EBITDA (US\$m)	PBT* (US\$m)	EPS* (c)	DPS (c)	P/E (x)	EV/EBITDA (x)
06/12	334	0	(9)	(1.1)	0.0	N/A	N/A
06/13	364	3	(6)	(1.3)	0.0	N/A	38.1
06/14e	389	11	3	0.2	0.0	145.8	11.1
06/15e	420	18	11	0.8	0.0	32.5	7.1

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

Tenon delivering improved results

Tenon forms the bulk of Rubicon's results and reported FY13 numbers confirmed a strengthening financial performance as the year progressed, consistent with a US housing market recovery. EBITDA rose by US\$3m to US\$5m following revenue growth of 9%; the US newbuild/pro-dealer segment was the most active, with remodelling/home improvement retail beginning to improve toward the period end. Australasian trading benefited from both volume growth and mix improvements.

Tenon is well positioned for the next stage of the US cyclical upturn, having increased operational efficiency, invested in inventory and put new banking facilities in place. Our Tenon estimates have risen, driven by underlying trading upgrades and more favourable exchange rates and this is reflected in our revised Rubicon estimates.

Growing and maturing ArborGen business model

Newsflow for ArborGen is positive on a number of fronts. Seedling volume growth with an increased proportion of advanced genetics drove revenue growth of 14% in FY13, with an US\$8m EBITDA contribution (pre-R&D and central costs). Integrating CellFor has enhanced strategic focus with faster commercialisation of advanced products targeted in the US. Scale eucalyptus production in Brazil is now to begin in CY14. A neutral fully expensed EBITDA position is ArborGen's target for FY14.

This should reduce the funding required from shareholder partners, and with banking facilities now in place to 2015, ArborGen's business model is starting to mature. Rubicon has stated that an IPO of ArborGen remains a strategic priority.

Valuation: Investment performance reinforces upside

Since our [initiation note](#) in June, Rubicon's share price has risen by 21% (Tenon is up 30%, at NZ\$1.43). At current prices, ArborGen's implied c US\$220m value (or NZ\$0.23 per RBC share) sits at a sizeable discount to our previously outlined c US\$360m (existing markets) and c US\$300m (new markets) valuations, together equivalent to c NZ\$0.69 (at NZ\$/US\$ 0.795) per RBC share. If we also factor in our revised Tenon valuation (mid-point c NZ\$0.24 per RBC share) and adjust for c NZ\$0.04 per share debt, there remains clear upside from current levels.

Building materials & agricultural

17 September 2013

Price **NZ\$0.34**
Market cap **NZ\$129m**

US\$0.795/NZ\$

 Net debt (US\$m) as at June 2013 61
(consolidated)

Shares in issue 379.7m

Free float 77%

Code RBC

Primary exchange NZX

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 0.0 21.4 21.4

Rel (local) (3.3) 15.2 3.1

52-week high/low NZ\$0.38 NZ\$0.25

Business description

Rubicon is a forestry investment company with holdings in Tenon (NZ-listed, US-focused appearance wood product distributor) and ArborGen (an international developer and supplier of advanced forestry seedlings).

Next events

ASM December 2013

Analysts

Toby Thorrington +44 (0)20 3077 5721

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com
[Edison profile page](#)

Moving in the right direction

Rubicon fully consolidates the earnings of Tenon (59%-owned) with minority deductions and this forms the bulk of its financial statements. ArborGen (31.67%-owned) is treated as an associate investment and carried as a non-current asset; as adjusted PAT (after capitalising product costs) is around zero, no associate profit or loss line is visible. Partner funding payments appear as an investment in associate in Rubicon's cash flow statement. At the group level, Rubicon recorded a much-improved operating loss of US\$1m in FY13 (versus US\$10m in FY12) before US\$5m finance costs resulted in a pre-tax loss of US\$6m (US\$14m in FY12).

Tenon's recovery is underway

A year that started tentatively in trading terms ended strongly for Tenon with accelerating revenue growth and improving profitability. This was achieved despite some tightness in the supply chain, absorbing c US\$1m business re-engineering costs and an adverse average NZ\$/US\$ rate (causing an estimated further US\$1m drag on reported results). North American and Australasian operations both made progress, with EBITDA increasing from US\$1m in H1 to US\$4m in H2 (compared to US\$2m for FY12 as a whole). Further progress is anticipated; upgrades to our existing underlying estimates are enhanced by a stronger prevailing US dollar (NZ\$/US\$ assumption moving from 0.82 to 0.795). Consequently, our FY14 and FY15 EBITDA expectations for Tenon are now US\$13m and US\$20m respectively (up c US\$1m and US\$4m respectively compared to our previous estimates).

Strategically, Tenon remains well placed to benefit from a broadening out of the US housing market into remodelling sectors and has invested in increased inventory to maintain service levels into the next phase of recovery. In the near term, management has elected to focus on realising gains from operational efficiency improvements and enhanced market shares made in the US in recent years as volumes return toward mid-cycle levels. While a possible entry into China is still under active review, in the near term the company will be focusing its resources on the recovering US housing market where earnings leverage is greatest. After the FY13 results, Tenon announced revised banking facilities (expanded from US\$54 to US\$70m, with a five-year term to September 2018), which provides clear funding visibility for the ongoing US housing recovery. We discuss Tenon's FY13 results and prospects in more detail in a recently published update note, [Healthy upside](#).

ArborGen is making progress on a number of fronts

ArborGen is a 31.67%-owned associate and is a private company, so does not report full results independently.

Revenue growth and developing mix: Rubicon states that ArborGen's revenues grew by 14% (to US\$30m) in the year with an increase in the volume of seedlings sold of 9.5% (to 273m). The US is the largest market served (c 90% of volume), and within this, loblolly pine (chiefly for south-east US plantation forests) is the dominant species, accounting for 90% of FY13 US sales volumes. ArborGen's advanced genetics seedling sales in the region rose by 80% (to 29m) in the year and ArborGen is targeting a further 50% increase in FY14. This strategic sales migration from traditional, open pollinated seedlings to those produced from advanced genetics (using mass control pollination and varietal techniques) means that average selling prices should rise materially over time – as already seen in the NZ market – and this mix shift will have contributed to the implicit 4% increase in average seedling price in FY13.

Improving financial performance: ArborGen achieved earnings before R&D and corporate overhead of US\$8m. An R&D review in FY13 has scaled back longer-term research project spend, in favour of increased resource being focused on commercialising advanced genetics seedlings. Rubicon and its two other shareholder partners each contributed c US\$4m in FY13 to fund ArborGen's ongoing business development. Its year-end net debt position is understood to have

been lower yoy (in the low-US\$20m range). Note that ArborGen management is targeting a neutral EBITDA position in FY14 after expensing all R&D and corporate costs. This would be a major milestone in the company's development toward a standalone business entity and maturing business model. As a result, the cash call on partner investors should start to reduce from FY14.

Visible funding arrangements: We view the revised and extended banking facilities of ArborGen as significant. With visible banking arrangements in place through to late-2015 (US\$26m to August in the US, NZ\$4.5m to November in New Zealand) management has flexibility to develop the business further and to choose an appropriate time for its IPO.

Fresh strategic impetus: The acquisition of CellFor (in August 2012) appears to have been a seminal development both in its own right (bringing in pine varietal seedling technology in North America and South America) and in the context of ArborGen's refocused strategic direction. The R&D emphasis is now biased toward the faster commercialisation of ArborGen's enlarged advanced (non-GE) seedling portfolio. Advanced biotechnology techniques (including predictive genomic selection) materially shorten the development cycle timeline to reach the production phase earlier. Additionally, non-GE advanced seedlings do not require regulatory approval further reducing the time to commercialisation. With a strengthened management team in place to execute this programme and a structured approach to market development, the US and Brazil are the primary geographies targeted (as already active and advanced), with China and Europe possible future regional extensions.

Rubicon's annual cash requirements expected to reduce

Rubicon ended FY13 with consolidated net debt of US\$61m, of which US\$12m resides in Rubicon and US\$49m in Tenon (non-recourse). This represented a c US\$8m reduction in holding company debt, US\$15m net new equity funding¹ early in the year net of central costs (US\$2m), interest (US\$1m) and associate funding (US\$4m).

In FY14, ArborGen's cash funding requirements may be lower than FY13, indicating that Rubicon should continue to operate within its existing borrowing facilities (of US\$20m, term ending 1 July 2014). In the event that ArborGen's development is slower than currently anticipated and additional partner funding is required, this may need to be revisited. The other side of the coin is that once ArborGen becomes cash neutral/positive, Rubicon's annual cash outflow should be modest. At some point, we would expect cash inflows to occur either as Tenon returns to paying dividends and/or there is a valuation event that enables Rubicon to monetise some of the value in one or other of its investments.

Tenon recovery mirrored in Rubicon estimate upgrades

As outlined earlier, Tenon's financial performance is the primary driver of Rubicon's own reported results. Having put through post-FY13 result upgrades for Tenon, we now reflect this in our Rubicon estimates. As shown in Exhibit 1, we anticipate a material uplift in earnings – both against previous years and previous estimates – in FY14 and FY15.

Exhibit 1: Rubicon revised estimates

	EPS*			PBT			EBITDA		
	Old	New	% chg	Old	New	% chg	Old	New	% chg
2013	(1.2)	(1.3)		(5)	(6)		3	3	
2014e	0.0	0.2	N/M	2	3	+50%	10	11	+10%
2015e	0.7	0.8	+14%	6	11	+83%	14	18	+29%

Source: Edison Investment Research. *Note: previous estimate did not include a Tenon tax charge for FY15.

¹ Equivalent to NZ\$21m net, via a 1:3 rights issue at NZ\$0.22, Theoretical ex-rights price c NZ\$0.34.

Exhibit 2: Financial summary

	US\$m	2011	2012	2013	2014e	2015e	2016e
June		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS							
Revenue		326	334	364	389	420	454
Cost of Sales		(241)	(252)	(281)	(294)	(315)	(338)
Gross Profit		85	82	83	94	105	117
EBITDA		6	0	3	11	18	25
Operating Profit (before GW and except.)		(0)	(5)	(1)	8	14	22
Intangible Amortisation		0	0	0	0	0	0
Exceptionals		0	(5)	0	0	0	0
Associate		(1)	0	(0)	0	0	1
Operating Profit		(1)	(10)	(1)	8	15	23
Net Interest		(4)	(4)	(5)	(4)	(4)	(4)
Profit Before Tax (norm)		(5)	(9)	(6)	3	11	19
Profit Before Tax (FRS 3)		(5)	(14)	(6)	3	11	19
Tax		(1)	2	0	0	(4)	(7)
Profit After Tax (norm)		(6)	(7)	(6)	3	7	12
Profit After Tax (FRS 3)		(6)	(12)	(6)	3	7	12
Average Number of Shares Outstanding (m)		285.0	284.8	378.5	379.7	379.7	379.7
EPS - normalised (c)		(1.8)	(1.1)	(1.3)	0.2	0.8	1.7
EPS - FRS 3 (c)		(1.8)	(2.8)	(1.3)	0.2	0.8	1.7
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		26.1	24.6	22.8	24.3	25.0	25.7
EBITDA Margin (%)		1.8	0.0	0.8	2.8	4.2	5.6
Operating Margin (before GW and except.) (%)		0.0	-1.5	-0.3	1.9	3.4	4.8
BALANCE SHEET							
Fixed Assets		189	196	199	201	202	202
Intangible Assets		85	85	85	85	85	85
Tangible Assets		29	25	23	22	20	19
Investments		75	86	91	94	97	98
Current Assets		82	87	106	112	120	134
Stocks		53	53	72	75	81	87
Debtors		22	29	33	35	38	41
Cash		2	0	0	0	0	6
Current Liabilities		(36)	(35)	(49)	(53)	(55)	(58)
Creditors		(27)	(33)	(46)	(47)	(49)	(52)
Short term borrowings		(9)	(2)	(3)	(6)	(6)	(6)
Long Term Liabilities		(31)	(57)	(58)	(58)	(58)	(58)
Long term borrowings		(31)	(57)	(58)	(58)	(58)	(58)
Other long term liabilities		0	0	0	0	0	0
Net Assets		204	191	199	202	209	221
CASH FLOW							
Operating Cash Flow		3	(4)	(10)	7	12	19
Net Interest		(5)	(3)	(4)	(4)	(4)	(4)
Tax		(1)	0	0	0	(4)	(7)
Capex		(2)	(2)	1	(2)	(2)	(2)
Acquisitions/disposals		(4)	(9)	(4)	(4)	(2)	0
Financing		0	(1)	15	0	0	0
Dividends		0	0	0	0	0	0
Net Cash Flow		(8)	(19)	(2)	(3)	0	6
Opening net debt/(cash)		30	38	59	61	64	64
HP finance leases initiated		0	0	0	0	0	0
Other		0	(2)	0	0	(0)	(0)
Closing net debt/(cash)		38	59	61	64	64	58

Source: Edison Investment Research, Rubicon accounts

Edison, the investment intelligence firm, is the future of investor **interaction with corporates**. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Rubicon and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2013. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.